New head/neck cancer treatment begins clinical trials
David Raben, MD, and Antonio Jimeno, MD, of the University of Colorado Cancer Center have begun a clinical trial that tests the combination of a DNA repair inhibitor, a growth factor inhibitor, and intensity-modulated radiation therapy (IMRT) for improved treatment of head and neck cancer. When used in conjunction with IMRT, the DNA repair inhibitor olaparib prevents cancer cells from repairing themselves after radiation treatment, according to the researchers. For

